Multiple myeloma (MM) is still incurable B-cell malignancy affecting more than 14,000 Americans annually. Myeloma tumor cells can survive even the most aggressive treatment available today, leading to disease relapses. The long-term goal of this project is to develop more effective cytostatic therapies to eradicate myeloma cells. We recentiy made a novel and exciting discovery that anti-p2-microglobulin (P2M) monoclonal antibodies (mAbs) had strong apoptotic activity in both established myeloma cell lines and primary myeloma cells from patients. The mAbs selectively target and kill myeloma cells in coculture with normal hematopoietic cells without damaging normal blood cells, including CD34+ stem cells. Anti-p2M mAbinduced apoptosis in myeloma cells were not blocked by soluble p2M (10-100 ng/mL, 3- to 30-fold higher than that in most MM patients, which are about 3 jag/mL), IL-6, or other myeloma growth and survival factors. The mAbs induced cell death via inhibiting P13K/Akt and ERK, activating JNK, and compromising mitochondrial integrity, leading to cytochrome c release and activation of a caspase-9-dependent cascade. Furthermore, the mAbs were also active and therapeutic in vivo in xenograft mouse models of myeloma. Thus, we hypothesize that anti-p2M mAbs may be used as therapeutic agents to treat patients with MM. This hypothesis will be tested by the following aims.
Aim 1 will examine the mechanisms of anti-p2M mAbinduced apoptosis in myeloma cells. Using normal plasma or B cells as controls, we will define the role of surface MHC class I and class l-like molecules in these responses, and examine surface proteins binding to, the downstream kinases, and intracellular signaling and apoptosis pathways induced by anti-p2M mAbs.
Aim 2 will utilize immune effector cells or molecules to enhance the efficacy of anti-p2M mAbs, Aim 3 will develop strategies to enhance the efficacy of anti-p2M mAbs to induce apoptosis in myeloma cells by combining with novel antimyeloma agents, and Aim 4 will perform pre-clinical and clinical studies to examine the safety and toxicity profiles of the mAbs.

Public Health Relevance

These novel studies may lead to the development of anti-p2M mAbs as the first clinically useful and effective therapeutic mAbs for treating MM and potentially other malignancies that express surface p2M and MHC class I molecules.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Xia, Yi; Jeffrey Medeiros, L; Young, Ken H (2016) Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochim Biophys Acta 1865:58-71
Xu-Monette, Zijun Y; Zhang, Shanxiang; Li, Xin et al. (2016) p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging (Albany NY) 8:345-65
Kanagal-Shamanna, Rashmi; Xu-Monette, Zijun Y; Miranda, Roberto N et al. (2016) Crystal-storing histiocytosis: a clinicopathological study of 13 cases. Histopathology 68:482-91
Cao, Xin; Medeiros, L Jeffrey; Xia, Yi et al. (2016) Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leuk Lymphoma 57:1104-13
Zhang, Xing-Ding; Baladandayuthapani, Veerabhadran; Lin, Heather et al. (2016) Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell 29:639-52
Zhou, Liang; Chen, Shuang; Zhang, Yu et al. (2016) The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR. Blood 127:2219-30
Ye, Qing; Xu-Monette, Zijun Y; Tzankov, Alexandar et al. (2016) Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget 7:2401-16
Tang, Jinle; Li, Jialu; Zhu, Xuejun et al. (2016) Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells. Oncotarget 7:34070-83
Shah, Jatin J; Jakubowiak, Andrzej J; O'Connor, Owen A et al. (2016) Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res 22:34-43
de Winde, Charlotte M; Veenbergen, Sharon; Young, Ken H et al. (2016) Tetraspanin CD37 protects against the development of B cell lymphoma. J Clin Invest 126:653-66

Showing the most recent 10 out of 169 publications